BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26136482)

  • 1. Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study.
    Littlejohn G; Roberts L; Bird P; de Jager J; Griffiths H; Nicholls D; Young J; Zochling J; Tymms KE
    J Rheumatol; 2015 Sep; 42(9):1603-9. PubMed ID: 26136482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control.
    Littlejohn G; Roberts L; Arnold M; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Scott J; Zochling J; Tymms KE
    Int J Rheum Dis; 2013 Oct; 16(5):532-8. PubMed ID: 24164840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
    Haugeberg G; Hansen IJ; Soldal DM; Sokka T
    Arthritis Res Ther; 2015 Aug; 17(1):219. PubMed ID: 26290061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022.
    Littlejohn G; Anbumurali N; O'Sullivan C; Smith T; Tymms K; Bird P; Nicholls D; Griffiths H
    Clin Rheumatol; 2024 Jun; 43(6):1823-1832. PubMed ID: 38634966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
    Kaneko Y; Kondo H; Takeuchi T
    J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
    Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
    Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.
    Behrens F; Tony HP; Alten R; Kleinert S; Scharbatke EC; Köhm M; Gnann H; Tams J; Greger G; Burkhardt H
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1608-16. PubMed ID: 23609999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical profile of 266 Filipino patients with rheumatoid arthritis included in the rheumatoid arthritis database and registry (RADAR) of the Philippine General Hospital.
    Penserga EG; Natividad TA; Salido ES;
    Int J Rheum Dis; 2015 May; 18(4):433-8. PubMed ID: 26010598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?
    Linde L; Sørensen J; Østergaard M; Hørslev-Petersen K; Hetland ML
    J Rheumatol; 2010 Feb; 37(2):285-90. PubMed ID: 20080905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.